The dual antiplatelet therapy (DAPT) score was developed to estimate ischemic and bleeding risks from the DAPT study. However, few studies validated its utility externally. We sought to validate the utility of the DAPT score in the Japanese population.
D
ual antiplatelet therapy (DAPT) with aspirin and thienopyridine has been the standard care to prevent stent thrombosis (ST) in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stent (DES). 1, 2 In addition, extended DAPT is expected to reduce ischemic events such as myocardial infarction (MI) and possibly stroke in patients with advanced atherosclerotic after PCI. 1, 3, 4 However, the optimal duration of DAPT after PCI with DES still remains a matter under debate. The DAPT study reported that prolonged DAPT reduced ischemic adverse events but increased bleeding events. 3 It is challenging to identify who derives benefit or harm from prolonged DAPT because the predictive factors for ischemic and bleeding events often overlap. 5 In the DAPT study, Yeh et al 6 recently developed the DAPT score to estimate both the ischemic and bleeding risks with a single scoring system. The DAPT score successfully identified the 2 groups of patients internally within the DAPT study, in whom DAPT continuation beyond 1 year provided benefit of ischemic protection and in whom it caused harm from bleeding. 3, 6 However, the DAPT score has not been adequately validated externally outside the DAPT study. Furthermore, it is unclear whether prolonged DAPT guided by the DAPT score can reduce ischemic events in populations outside the DAPT study. Therefore, we sought to examine the utility of the DAPT score for stratifying the ischemic and bleeding risks and for guiding the duration of DAPT after DES implantation in a large pooled cohort from the 3 Japanese PCI studies.
METHODS

Study Population
We constructed a pooled database of 22 386 patients using the patient-level data from the 3 Japanese studies [7] [8] [9] conducted by the same group of investigators, in which the status of antiplatelet therapy was consistently evaluated during the follow-up: the CREDO-Kyoto (Coronary Revascularization Demonstrating Outcome Study in Kyoto) PCI/CABG Registry Cohort-2 (Percutaneous Coronary Intervention/ Coronary Artery Bypass Grafting) (N=15 939), the RESET trial (Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent) (N=3206), and the NEXT (NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-Eluting Stent Trial) (N=3241). The CREDO-Kyoto PCI/CABG Registry Cohort-2 is a multicenter observational registry that enrolled consecutive patients undergoing their first coronary revascularizations (January 2005-December 2007). RESET is a randomized controlled trial that compared sirolimus-with everolimus-eluting stent without any exclusion criteria (February-July 2010). NEXT is a randomized controlled trial that compared everolimus-with biolimus-eluting stent without any exclusion criteria (May-October 2011). The followup durations were 5 years in the CREDO-Kyoto PCI/CABG Registry Cohort-2 and 3 years in RESET and NEXT. For constructing the pooled database, the follow-up period was truncated at 3 years to standardize the follow-up duration. The study results and other details were previously reported [7] [8] [9] and summarized in Table I in the online-only Data Supplement.
The Kaplan-Meier curves for the clinical outcomes during the entire 3-year follow-up in the study group of 12 941 patients are presented in Figure I in the online-only Data Supplement. The current study population consists of 12 223 patients who underwent successful PCI with DES, received DAPT at discharge, and were alive without MI, ST, or major bleeding events at 13 months after DES implantation ( Figure 1) . We evaluated the distribution of the DAPT score and compared the risks for ischemic and bleeding events beyond 13 months according to the 2 DAPT score categories (high DS versus low DS).
We also evaluated the association between DAPT status and ischemic and bleeding events beyond 13 months in the 2 DAPT score categories. Because the DAPT duration was determined by physicians and because the patient characteristics were different, we developed propensity score-matched cohorts of 5704 patients (N=1590 in high DS and N=4114 in low DS, evenly divided into on DAPT and off DAPT at 13 months) as the main set of exploratory analysis.
Baseline and Follow-Up Information and Definition of Clinical Events
In all 3 studies, most of the baseline and follow-up information was obtained from the hospital chart; for patients without a hospital visit, the follow-up information was collected by mail questionnaire or telephone to the patients and the referring physicians. MI was adjudicated by the definition of the ARTS (Arterial Revascularization Therapies Study) 10 in the CREDOKyoto PCI/CABG Registry Cohort-2 and by the definition of Academic Research Consortium (ARC) consensus criteria 11 in RESET and NEXT. The definitions for the end points other than MI were identical across the 3 studies. Stent thrombosis was
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What Is New?
• We sought to validate the dual antiplatelet therapy (DAPT) score, which was developed to stratify the risks for ischemic and bleeding events with a single scoring system and to guide DAPT duration. • In the pooled cohort of the current study, the incidence of primary ischemic end point was significantly higher in the high-than in the low-DAPT score, whereas the cumulative incidence of the primary bleeding end point tended to be lower in the high-than in the low-DAPT score.
What Are the Clinical Implications?
• In the current population composed of the 3 studies in Japan, the DAPT score successfully stratified the risks for both ischemic and bleeding events, although the ischemic event rate in the current population was remarkably low even in the high-DAPT score.
• Further studies would be warranted to evaluate the utility of prolonged DAPT guided by the DAPT score.
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defined according to the definition of the ARC. 11 Death was regarded as cardiac in origin unless obvious noncardiac causes could be identified. Stroke during follow-up was defined as ischemic or hemorrhagic stroke requiring hospitalization with symptoms lasting >24 hours. Bleeding was defined according to the GUSTO classification (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries). 12 The clinical events were adjudicated by independent clinical event committees. Each study protocol was approved by the institutional review boards in all the participating centers. In the CREDO-Kyoto PCI/CABG Registry Cohort-2, written informed consent from the patients was waived because of its retrospective enrollment, although those who refused participation when contacted for follow-up were excluded. In RESET and NEXT, written informed consents were obtained from all the study subjects.
DAPT Score Calculation
The details of the DAPT score calculation were reported previously. 6 Briefly, the score, ranging from -2 to 10, assigned points as follows: 0 point for patients <65 years of age; -1 point for 65 to <75 years of age; -2 point for patients ≥75 years of age; 2 points for vein graft stenting and history of congestive heart failure or left ventricular ejection fraction (LVEF) <30%; and 1 point for current cigarette smoker or within a year, diabetes mellitus, MI at presentation, stent diameter <3 mm, prior PCI or MI, and paclitaxel-eluting stent. The study patients were separated into the 2 categories previously reported 6 : DAPT score ≥2 (high DS) and DAPT score <2 (low DS). As an exploratory subgroup analysis, the low-DS group was further divided into DAPT score=1 (middle DS) and DAPT score <1 (very low DS). In the current data set, the data on LVEF was lacking in a significant proportion of patients (N=1895, 15.5%). To avoid exclusion of those patients without LVEF data, we regarded those patients as having LVEF ≥30% when they did not have a history of congestive heart failure. Calculation of the DAPT score was performed by 2 physicians (Y.Y. and H.W.) in a fashion blinded to the clinical outcomes.
Antithrombotic Therapy
Procedural anticoagulation was achieved with unfractionated heparin following the local site protocols. The recommended antiplatelet regimen included aspirin (≥81 mg daily) indefinitely and thienopyridines (75 mg clopidogrel or 200 mg ticlopidine daily) for ≥3 months in RESET and NEXT. There was no specific protocol-recommended antiplatelet therapy in the CREDO-Kyoto PCI/CABG Registry Cohort-2 because of its retrospective observational study design. The actual duration of DAPT was left to the discretion of each attending physician in all the studies. The status of antiplatelet therapy was evaluated throughout the follow-up period. Discontinuation of aspirin or thienopyridine was defined to be persistent when withdrawn for ≥2 months. 13 Discontinuation of DAPT was defined as persistent discontinuation of either aspirin or thienopyridine.
Outcome Measures
The primary ischemic end point was defined as a composite of MI (defined by the ARTS in the CREDO-Kyoto PCI/CABG Registry Cohort-2 and by the ARC criteria in RESET and NEXT) and definite/probable ST (defined by the ARC criteria).
10,11
The primary bleeding end point was defined as moderate or severe bleeding by the GUSTO classification. 12 The secondary end point included the individual components of the primary end points, all-cause death, cardiac death, noncardiac death, and stroke. The detailed definitions of these end points are described in this report and presented previously. 
Statistical Analysis
Categorical variables were presented as counts and percentages and were compared by the χ 2 test or Fisher exact test. Continuous variables were presented as mean±SD or median with interquartile range. Continuous variables were compared using the Student t test or Wilcoxon rank-sum test depending on their distributions. Cumulative incidences of events were estimated by the KaplanMeier method, and the differences were assessed by the log-rank test. To evaluate clinical outcomes beyond 1 year, we conducted a so-called landmark analysis at 13 months, taking a window period of 1 month because the patients in the DAPT study and those in our previous study were allocated in similar timelines. 3, 14 As an exploratory analysis, we sought to evaluate the association between longer DAPT and clinical outcomes in patients with high DS and low DS, respectively. We divided the patient population into 2 groups according to the DAPT status at 13 months (on DAPT, N=3149 in high DS and N=6222 in low DS; off DAPT, N=795 in high DS and N=2057 in low DS). We used the logistic regression model to develop a propensity score for the choice of DAPT status at the landmark point in each DAPT score category with 23 variables relevant to the DAPT choice listed in Tables II  and III in the online-only Data Supplement. Missing data were considered as negative values for binary covariates, because the numbers of missing data were negligibly small (maximum of 89 out of 12 223 patients for the variable of hemoglobin <11 g/ dL). The propensity score was calculated by summing up all the coefficients multiplied by corresponding variables. To create the propensity score-matched cohort, the patients on DAPT at 13 months were matched to those without DAPT at 13 months using the 1:1 greedy matching technique. 15 Then we calculated the cumulative incidences of the primary end points and their individual components by the Kaplan-Meier method, and the differences were assessed by the log-rank test.
We conducted an additional sensitivity analysis using the Cox proportional hazard model with DAPT status as a timeupdated covariate. We estimated the risks of on DAPT relative to off DAPT for the primary end points by the multivariable Cox proportional hazard model by DAPT status at 13 months as on versus off approach (model 1), and by the multivariable Cox proportional hazard model with DAPT status beyond 13 months as a time-updated covariate (model 2), using the same clinically relevant variables listed in Tables II and III in the onlineonly Data Supplement. The detailed methods were described in the Methods and Results in the online-only Data Supplement).
The statistical analyses were conducted by 2 physicians (Y.Y. and H.W.) and a statistician (T.M.). The propensity score was calculated with SAS 9.4 (SAS Institute Inc.). The multivariable Cox proportional hazard model with stratification variable and timeupdated covariate was performed with SPSS version 19 (IBM Corp.). All the other analyses were performed with JMP version 13.1 (SAS Institute Inc.). All the reported P values were 2-sided, and P values <0.05 were considered statistically significant.
RESULTS
Baseline Characteristics: High-Versus Low-DAPT Score Categories
Among the 12 223 study patients, 3944 (32%) had high DS and 8279 (68%) had low DS (Figure 2 ). The The bar chart represents the proportion of the patients in each DAPT score. In each DAPT score category, the patients were divided into 2 groups according to the DAPT status at the 13-month landmark point (on DAPT and off DAPT). CHF indicates congestive heart failure; DAPT, dual antiplatelet therapy; LVEF, left ventricular ejection fraction; MI, myocardial infarction; and PCI, percutaneous coronary intervention. high-DS group had a significantly higher proportion of patients with acute MI at presentation, diabetes mellitus, current smoking, history of congestive heart failure, LVEF <30%, prior MI, and hemodialysis than the low-DS group, whereas the low-DS group had a significantly higher proportion of patients with advanced age, female sex, prior stroke, peripheral artery disease, atrial fibrillation, malignancy, and anemia than the high-DS group. Regarding the procedure characteristics, the high-DS group generally had more complex features, such as a higher proportion of multivessel disease and a longer stent length than the low-DS group. Medications such as statins, β-blockers, and angiotensinconverting enzyme inhibitors or angiotensin receptor blockers were more often prescribed in the high-DS than in the low-DS group (Table 1) .
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Clinical Outcomes by the 13-Month Landmark Analysis: High-Versus Low-DAPT Score Categories
The cumulative 3-year incidence of the primary ischemic end point beyond 13 months after PCI was significantly higher in the high-DS than in the low-DS group (1.5% versus 0.9%, log-rank P=0.002), although the event rate was remarkably low even in the high-DS group (Figure 3A and Table 2 ). The cumulative 3-year incidence of the primary bleeding end point beyond 13 months after PCI tended to be lower in the high-DS than in the low-DS group without a statistically significant difference (2.1% versus 2.7%, log-rank P=0.07) ( Figure 3B and Table 2 ). Regarding the secondary outcome measures, the high-DS group was associated with significantly higher cumulative 3-year incidences of cardiac death, MI, and definite/probable ST than the low-DS group (2.0% versus 1.4%, log-rank P=0.03; 1.5% versus 0.8%, log-rank P=0.002; 0.7% versus 0.3%, log-rank P<0.001, respectively), whereas the low-DS group was associated with significantly higher cumulative 3-year incidences of noncardiac death and GUSTO severe bleeding than the high-DS group (2.4% versus 3.9%, log-rank P<0.001; 1.0% versus 1.6%, log-rank P=0.03, respectively) ( Table 2 ).
In the additional analysis stratified by the 3 DAPT score categories (high DS, middle DS, and very low DS), the Kaplan-Meier curves diverged in order of the DAPT score categories for both the primary ischemic end point and the primary bleeding end point ( Figure II in the online-only Data Supplement).
Baseline Characteristics and Clinical Outcomes in Propensity Score-Matched Cohort According to DAPT Status at 13 Months
In both the high-DS (N=3944) and low-DS (N=8279) groups, large proportions of patients ( (Figure 2 ). Compared with the off-DAPT group (N=795 and N=2057, respectively), the on-DAPT group included more patients with diabetes mellitus, prior MI, prior stroke, hemodialysis, and target of left main coronary artery lesion but fewer patients with acute MI at presentation and liver cirrhosis. The stent types and medications were also significantly different between the on-and off-DAPT groups, reflecting the higher prevalence of newer studies such as RESET and NEXT in the on-DAPT group (Tables II and III in the online-only Data Supplement). The baseline characteristics of the on-and off-DAPT groups in the propensity score-matched cohorts in each score category were much more comparable than those in the entire cohort (Tables IV and V in the onlineonly Data Supplement).
In the propensity score-matched high-DS cohort, the cumulative 3-year incidence of the primary ischemic end point tended to be lower in the on-than off-DAPT group (0.9% versus 1.9%, log-rank P=0. 10) , whereas that of the primary bleeding end point was not different between the on-and off-DAPT groups (1.9% versus 2.2%, log-rank P=0.76) (Figure 4 and Table 3 ).
Conversely, in the propensity score-matched low-DS cohort, the cumulative 3-year incidence of the primary bleeding end point tended to be higher in the on-than in the off-DAPT group (3.2% versus 2.3%, log-rank P=0.08), whereas that of the primary ischemic end point was not different between the on-and off-DAPT groups (0.8% versus 1.0%, log-rank P=0.51) ( Figure 5 and Table 4 ).
In the sensitivity analyses using multivariable Cox proportional hazard models, none of the hazard ratios or interactions was significant, as in the propensity score-matched analyses. The detailed results are shown in Table VI in the online-only Data Supplement).
DISCUSSION
The main findings of the current study were as follows: (1) the DAPT score successfully stratified the ischemic and bleeding risks beyond 1 year after PCI with DES in the Japanese population; (2) the event rate of MI and ST in the present study was remarkably low even in patients with high DS; (3) in the propensity score-matched cohort, the on-DAPT group at 13 months compared with the off-DAPT group tended to be at a lower risk for ischemic events in high DS and at a higher risk for bleeding events in low DS, although the differences were not statistically significant. The cumulative 3-year incidences of the primary ischemic end point (A) and the primary bleeding end point (B) by the 13-month landmark analysis: high-versus low-DAPT score categories. The cumulative 3-year incidence of the primary ischemic end point (a composite of myocardial infarction or definite/probable stent thrombosis) was significantly higher in the patients with a high-DAPT score than in those with a low-DAPT score, whereas that of the primary bleeding end point (GUSTO moderate/severe bleeding) tended to be lower in those with a high-DAPT score than in those with a low-DAPT score without statistically significant difference. DAPT indicates dual antiplatelet therapy; DES, drug-eluting stent; and GUSTO, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
In line with the DAPT study and its external validation cohort (PROTECT trial [Patient Related Outcomes With Endeavor Versus Cypher Stenting]), the DAPT score successfully stratified the long-term risk for the ischemic events beyond 1 year after PCI with DES in this additional external validation cohort of the Japanese population.
6,16
Figure 4. The cumulative 3-year incidences of the primary end points in the propensity score-matched cohort of the high-DAPT score group. A, The cumulative 3-year incidence of the ischemic end point. B, The cumulative 3-year incidence of the bleeding end point. In the high-DAPT score group, the cumulative incidence of primary ischemic end point tended to be lower in the on-than in the off-DAPT group, whereas that of primary bleeding end point was not different between the on-and off-DAPT groups. DAPT indicates dual antiplatelet therapy; and DES, drug-eluting stent. 
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It would be important to note that the proportion of patients with high DS and their ischemic event rate from 1 year through 30 months were lower in the present study than in the DAPT study (32% versus 51% and 0.7% versus 3.0%, respectively). 6 Therefore, the absolute risk of ischemic events in patients with high or low DS could be different according to the ethnic and/or geographic differences. As to bleeding events, the DAPT score could discriminate the long-term bleeding risk internally in the DAPT study but not in the external validation cohort (the PROTECT trial). The discrepancy between the DAPT study and the PROTECT trial might be at least partly explained by the difference in the rate of bleeding events from 1 year through 30 months between the 2 studies (1.8% in the DAPT study, and 0.4% in high DS and 0.5% in low DS in the PROTECT trial). 6 Indeed, in the present study, there was a trend toward a higher bleeding risk in patients with low DS, in which the rate of bleeding events from 1 year through 30 months using the same end point definition was similar to that in the DAPT study (1.8% versus 1.8%). 6 Therefore, the DAPT score would also be applicable in the Japanese population for assessing both ischemic and bleeding risks.
Although the DAPT study demonstrated remarkable reduction in the ischemic events by the prolonged DAPT in the high-DS group, the ischemic risk of on DAPT in the high-DS group tended to be lower than that of off DAPT but was not statistically significant in the present study. This discrepancy might be at least partly explained by the difference in the rates of ischemic events from 1 year through 30 months in the high-DS groups between the 2 studies (2.7% versus 5.7% for continued thienopyridine versus placebo in the DAPT study; 1.1% versus 1.0% for on-versus off-DAPT in the present study). 6 As shown in the results, the overall ischemic event rate in the present study was lower than the bleeding event rate. In contrast, in the DAPT study as well as another study of prolonged DAPT, PEGASUS-TIMI 54 (Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54), 4 the overall ischemic event rates tended to be higher than the bleeding event rates. The lower risks for ischemic events in the present study might have influenced the association between longer DAPT and clinical outcomes. Another possible reason for the discrepancy between the DAPT study and the current study could be the difference in the clinical presentation of the patients. There were fewer patients with acute myocardial infarction in the current study (13%) than in the DAPT study (26%). 3 Taking these factors into consideration, the efficacy of prolonged DAPT for ischemic protection is still debatable.
Bleeding risks were also not significantly different between the on-and off-DAPT groups in the present study. However, in the low-DS group in the current study, the on-DAPT group compared with the off-DAPT group tended to be at a higher risk for the primary bleeding end point. In the DAPT study, prolonged DAPT compared with shorter DAPT was associated with a significantly higher bleeding risk and a trend toward increased mortality. In the ADAPT-DES study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents), bleeding after discharge after PCI was strongly associated with 2-year mortality (hazard ratio [HR], 5.03; 95% confidence interval [CI], 3.29-7.66), with an effect size greater than that of myocardial infarction after discharge (HR, 1.92; 95% CI, 1.18-3.12). 17 In the present study, the patients with low DS constituted a large proportion of the entire cohort. It might be more important to avoid bleeding events than to prevent ischemic events for a population at low ischemic risk and high bleeding risk such as the Japanese.
Limitations
The current study has several important limitations. First, all the studies involved in the current analyses did not randomize the duration of DAPT. Therefore, the results for the DAPT duration in this study are hypothesis generating because of its observational study design and lack of adequate power. The analysis does not really compare on versus off treatment during the follow-up period. Furthermore, >70% of patients continued DAPT independent of the DAPT score groups. It is likely that those who came off therapy were suspected to have higher bleeding risk, lower ischemic risk, or both. The result of this might be to bias any effect of DAPT continuation to the null. Therefore, the current analyses could not make any definitive conclusions about the effect of different DAPT durations on clinical outcomes in the 2 DAPT score categories. Second, the population of the current A, The cumulative 3-year incidence of the ischemic end point. B, The cumulative 3-year incidence of the bleeding end point. In the low-DAPT score group, the cumulative incidence of primary bleeding end point tended to be higher in the on-than in the off-DAPT group, whereas that of primary ischemic end point was not different between the on-and off-DAPT groups. DAPT indicates dual antiplatelet therapy; and DES, drug-eluting stent.
ORIGINAL RESEARCH ARTICLE pooled analyses consisted of the patients from a registry (the CREDO-Kyoto PCI/CABG Registry Cohort-2) and randomized controlled trials (RESET and NEXT), which were conducted in different time periods and contexts. Third, the definitions for MI were different between the CREDO-Kyoto PCI/CABG Registry Cohort-2 and the 2 randomized controlled trials (RESET and NEXT). MI was adjudicated by the definition of ARTS in the CREDOKyoto PCI/CABG Registry Cohort-2 and by the definition of ARC consensus criteria in RESET and NEXT. However, both the ARTS and ARC definitions adopted the same criteria for spontaneous MI (biomarker elevation above upper limit of normal). The present study evaluated clinical outcomes between 13 and 36 months after PCI, when the vast majority of adjudicated MI was not procedurerelated MI but spontaneous MI. Therefore, the difference in definitions of MI would not have affected the results in the present study. Fourth, a significant proportion of patients in this study received ticlopidine as thienopyridines, which is different from the current usual care. The results of this study might be less generalizable because of this difference in thienopyridine use. Fifth, risk adjustment by continuous variables theoretically improves the power to detect differences compared with that by dichotomized variables. However, we have consistently dichotomized the continuous variables in our previous reports. Finally, as discussed, the overall ischemic event rate in the present study was remarkably lower than that in the DAPT study and was ≈25% of that of the DAPT study. The difference in potential risk for ischemic events might have influenced the association between DAPT and ischemic events. Indeed, in the current 3 physician-directed studies, patients were not fully monitored, and the collection of clinical events was based on self-report by the site investigators. We could not exclude the possibility of underreporting clinical events. However, low rates of ischemic events have been reported consistently in the fully monitored company-directed postmarket surveillance registries of DES in Japan. 18, 19 
Conclusions
The DAPT score successfully stratified the ischemic and bleeding risks beyond 13 months after PCI with DES in the Japanese population, although the ischemic event rate was remarkably low even in the high-DAPT score group. Further studies would be warranted to evaluate the utility of prolonged DAPT guided by the DAPT score.
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